Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following BL-8040 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BioLineRx (BLRX) Bullish Stance Reiterated at Maxim Group After Entering Expansion stage of AML Phase 2 Study
May 4, 2015 11:46 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $8 price target on BioLineRx (NASDAQ: BLRX) after the company announced they have selected the 1.5 mg/kg dose of BL-8040 to move into the expansion phase of the ongoing phase II study in Acute Myeloid Leukemia (AML).
Kolbert highlighted:
With a... MoreBioLineRx (BLRX) Announces Completion of BL-8040 Phase 2 Dose-Escalation Stage
May 4, 2015 7:01 AM EDTBioLineRx (NASDAQ: BLRX) announced successful completion of the dose escalation stage of its ongoing Phase 2 study of BL-8040, and commencement of the expansion stage at the optimal dose of this novel treatment for acute myeloid leukemia (AML). Top-line results from the study are anticipated in the fourth quarter of 2015.
Results of the completed dose escalation stage, in which 22 patients participated, showed that all BL-8040 tested doses, up to 1.5 mg/kg, were found to be safe and well tolerated when administered in combination with Ara-C (Cytarabine). Building upon prior... More
